Search studies using keywords
1,851 Studies in the database containing data with -log p ≥ 0 (showing 181-200)
Pages: 1 2 3 4 5 6 7 8 9 10 >>
No data sets (in No Studies) added to Browser
Identifier Name Phenotype(s) Total p-values Related citationsAdd data sets to Browser Related data
HGVST1672 plus GWAS of Menarche (age at onset) 
  • Menarche (age at onset) (African American)
  • Menarche (age at onset) (European)
15
HGVST1673 plus GWAS of Bone mineral density 
  • Bone mineral density
1
HGVST1674 plus GWAS of PCA3 expression level 
  • PCA3 expression level
4
HGVST1675 plus GWAS of pigmentation traits and skin cancer 
  • Tanning
  • Eye color (Blue eye color)
  • Eye color (Brown eye color)
  • Non-melanoma skin cancer
  • Hair color
  • Eye color (Intermediate/Green eye color)
  • Sunburns
27
HGVST1668 plus GWAS of subcutaneous adipose tissue distribution in HIV-infected men 
  • Fat distribution (HIV) (univariate, upper trunk)
  • Fat distribution (HIV) (multivariate)
  • Fat distribution (HIV) (univariate, arm)
  • Fat distribution (HIV) (univariate, leg)
  • Fat distribution (HIV) (univariate, lower trunk)
17
HGVST1665 plus GWAS of Testicular germ cell tumor 
  • Testicular germ cell tumor
15
HGVST1666 plus GWAS of Alzheimer's disease biomarkers 
  • Alzheimer's disease biomarkers (ptau)
  • Alzheimer's disease biomarkers (tau)
6
HGVST1667 plus GWAS of Lipid metabolism phenotypes 
  • Lipid metabolism phenotypes (VLDL.medium, fasting)
  • Lipid metabolism phenotypes (IDL.total, whole)
  • Lipid metabolism phenotypes (LDL-C.assay, whole)
  • Lipid metabolism phenotypes (HDL.large, whole)
  • Lipid metabolism phenotypes (HDL-C.assay, whole)
  • Lipid metabolism phenotypes (VLDL.total, fasting)
  • Lipid metabolism phenotypes (TG.by.NMR, whole)
  • Lipid metabolism phenotypes (IDL.total, fasting)
  • Lipid metabolism phenotypes (APOB.assay, fasting)
  • Lipid metabolism phenotypes (VLDL.small, whole)
  • Lipid metabolism phenotypes (TG.by.NMR, fasting)
  • Lipid metabolism phenotypes (LDL.total, whole)
  • Lipid metabolism phenotypes (HDL.mean.size, fasting)
  • Lipid metabolism phenotypes (VLDL.total, whole)
  • Lipid metabolism phenotypes (APOA1.assay, fasting)
  • Lipid metabolism phenotypes (LDL.large, whole)
  • Lipid metabolism phenotypes (HDL.total, whole)
  • Lipid metabolism phenotypes (HDL-C.by.NMR, fasting)
  • Lipid metabolism phenotypes (HDL.mean.size, whole)
  • Lipid metabolism phenotypes (APOA1.assay, whole)
  • Lipid metabolism phenotypes (LDL-C.assay, fasting)
  • Lipid metabolism phenotypes (HDL.total, fasting)
  • Lipid metabolism phenotypes (HDL-C.assay, fasting)
  • Lipid metabolism phenotypes (LDL.large, fasting)
  • Lipid metabolism phenotypes (HDL.large, fasting)
  • Lipid metabolism phenotypes (VLDL.large, fasting)
  • Lipid metabolism phenotypes (TG.assay, whole)
  • Lipid metabolism phenotypes (VLDL.small, fasting)
  • Lipid metabolism phenotypes (TG.assay, fasting)
  • Lipid metabolism phenotypes (LDL.total, fasting)
  • Lipid metabolism phenotypes (HDL-C.by.NMR, whole)
  • Lipid metabolism phenotypes (VLDL.large, whole)
  • Lipid metabolism phenotypes (APOB.assay, whole)
73
HGVST1663 plus GWAS of Educational attainment 
  • Educational attainment (College)
  • Educational attainment (Edu Years)
13
HGVST1664 plus GWAS of Breast Cancer in BRCA1 mutation carriers 
  • Breast Cancer in BRCA1 mutation carriers
  • Ovarian cancer in BRCA1 mutation carriers
11
HGVST1658 plus GWAS of Self-employment 
  • Self-employment
2
HGVST1659 plus GWAS of Red blood cell traits 
  • Red blood cell traits (RBC count)
  • Red blood cell traits (MCH)
  • Red blood cell traits (MCV)
  • Red blood cell traits (MCHC)
7
HGVST1660 plus GWAS of Blood trace element (Cu levels) 
  • Blood trace element (Zn levels)
  • Blood trace element (Cu levels)
  • Blood trace element (Se levels) (Conditioned on rs921943)
  • Blood trace element (Se levels)
28
HGVST1661 plus GWAS of Heart rate 
  • QRS duration
  • Heart rate
  • QT interval
  • PR interval
31
HGVST1662 plus GWAS of Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) 
  • Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) (Allelic model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) (Dominant model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) (Dominant)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) (Allelic model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) (Dominant model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) (Recessive model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) (Recessive model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) (Allelic model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) (Allelic model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) (Allelic model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) (Recessive model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) (Allelic model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) (Dominant model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) (Dominant model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) (Recessive model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) (Recessive model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) (Allelic model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) (Dominant model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) (Allelic model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) (Allelic model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) (Recessive model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) (Dominant model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) (Recessive model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) (Allelic model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) (Dominant model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) (Allelic model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) (Dominant model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) (Allelic model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) (Allelic model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) (Recessive model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) (Dominant model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) (Recessive model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) (Dominant model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) (Dominant model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) (Recessive model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) (Dominant model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) (Recessive model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) (Dominant model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) (Recessive model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) (Allelic model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) (Dominant model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) (Dominant model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) (Recessive model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) (Allelic model)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) (Recessive model)
101
HGVST1652 plus GWAS of Obesity 
  • Obesity (WC)
  • Obesity (BMI)
3
HGVST1653 plus GWAS of Adiposity in newborns 
  • Adiposity in newborns (Birthweight, Model 2)
  • Adiposity in newborns (Sum of Skinfolds, Model 2)
  • Adiposity in newborns (Fat Mass, Model 2)
  • Adiposity in newborns (Sum of skinfolds, Model 3, Thai)
4
HGVST1654 plus GWAS of HDL cholesterol 
  • Hypertriglyceridemia
  • HDL cholesterol
14
HGVST1655 plus GWAS of Crohn's disease (need for surgery) 
  • Crohn's disease (need for surgery)
  • Crohn's disease (time to surgery)
3
HGVST1656 plus GWAS of Warfarin maintenance dose 
  • Warfarin maintenance dose
1